The approval of the treatment is based on two pivotal phase III clinical trials: M15-741 and M-15-736. Primary endpoint results from the first trial showed that...
The biopharmaceutical company Theranexus has just completed the Phase 2 trial of its THN102 drug candidate in Parkinson's disease. The study demonstrated the efficacy of THN102...
Pfizer has stopped its research on the possible cure for Parkinson's and Alzheimer's diseases.